Section 8.4: Treatment of Substance Use Disorders

Section 8.4: Treatment of Substance Use Disorders

The treatment of substance use disorders (SUD), particularly opioid use disorder (OUD), is subject to a strict intersection of federal and state laws. Pharmacists must distinguish between the legal parameters of dispensing controlled substances for pain management (analgesia) versus dispensing them for addiction treatment. Additionally, pharmacists must understand the peer assistance programs available for impaired colleagues.

Pain Management vs. Substance Use Disorder (SUD) Treatment

Federal and state laws establish a rigid boundary between prescribing controlled substances for analgesia and prescribing them for detoxification or maintenance of an addiction.

---

Methadone Dispensing Restrictions

Methadone is a Schedule II controlled substance.

• Analgesia: A practitioner may write a prescription for methadone for pain management, and a retail pharmacist may legally fill it. The prescription should ideally indicate "for pain" to clarify its legitimacy.
• SUD Treatment: A retail community pharmacy is strictly prohibited from dispensing a prescription for methadone if the intent is detoxification or maintenance of opioid addiction.
• Opioid Treatment Programs (OTPs): Patients receiving methadone for OUD must obtain it directly from an approved, registered OTP (commonly known as a methadone clinic). The medication is administered or dispensed on-site for take-home use under strict SAMHSA and DEA rules. A retail community pharmacy cannot act as a depot or pick-up site for methadone clinic patients.

---

Buprenorphine & The Mainstreaming Addiction Treatment (MAT) Act

Buprenorphine (either alone as Subutex or combined with naloxone as Suboxone) is a Schedule III controlled substance approved for OUD treatment.

Historical DATA 2000 Waiver

Historically, to prescribe buprenorphine for OUD, practitioners had to obtain a special waiver under the Drug Addiction Treatment Act of 2000 (DATA 2000). This waiver granted them an "X-DEA" number (the standard DEA registration starting with a different letter, replaced by 'X' for addiction treatment) and capped their active patient limits.

The MAT Act (December 2022 Update)

The federal Mainstreaming Addiction Treatment (MAT) Act (effective January 2023) completely eliminated the DATA-Waiver (X-DEA) requirement.

• Current Rule: Any prescriber with a standard DEA registration that includes Schedule III prescribing authority can write buprenorphine prescriptions for opioid use disorder.
• Pharmacist Duty: Pharmacists must not look for, require, or reject prescriptions based on the absence of an X-DEA number. Buprenorphine prescriptions for OUD are now processed and filled identically to standard Schedule III prescriptions. Standard retail pharmacies can stock and dispense buprenorphine for OUD.
• Clinical Nuance (Suboxone vs. Subutex): Subutex contains only buprenorphine and lacks the naloxone abuse-deterrent component. While both are Schedule III drugs, Subutex is primarily indicated for pregnant patients or those with documented naloxone allergies. Prescribing Subutex to non-pregnant patients without documented clinical necessity represents a diversion risk that pharmacists should verify with the prescriber.

---

The "Three-Day Rule" (Emergency Administration)

Under 21 CFR § 1307.31, a practitioner who is not registered as an OTP (and cannot prescribe buprenorphine under standard outpatient rules) may administer (but NOT prescribe) narcotic drugs to an addicted patient for the purpose of relieving acute withdrawal symptoms while arranging for referral to treatment.

Strict Limitations

1. Administration Only: The physician must administer the drug directly to the patient; they cannot write a prescription for the patient to fill at a pharmacy.
2. Quantity Limit: No more than a 1-day supply of the narcotic (e.g., methadone) may be administered at one time.
3. Time Limit: This emergency treatment can be conducted for a maximum of 72 hours (3 days). This 72-hour period cannot be renewed, extended, or repeated.

---

Office-Based Opioid Treatment (OBOT) Standards

Prescribers providing office-based treatment for opioid addiction must adhere to specific clinical guidelines issued by the Texas Medical Board (TMB). These rules mandate regular urine drug tests, psychiatric and psychological referral capabilities, and structured dosing protocols. When dispensing buprenorphine for SUD, pharmacists must still conduct the mandatory PMP search prior to dispensing, as buprenorphine is an opioid.

---

Impaired Pharmacists & The Professional Recovery Network (PRN)

Pharmacists have a professional and legal duty to protect the public from impaired practitioners. Under the Texas Occupations Code Chapter 564, the TSBP establishes a peer assistance program for pharmacy professionals.

The Professional Recovery Network (PRN)

PRN is the approved peer assistance program in Texas that handles cases of chemical dependency, substance abuse, and mental health issues among:

• Licensed pharmacists
• Registered pharmacy technicians and technician trainees
• Pharmacy students enrolled in accredited Texas colleges

Safe Harbor & Confidentiality

• Self-Reporting or Referral: If a pharmacist realizes they have a substance use disorder and self-reports to the PRN, or is referred by a colleague, they undergo evaluation and enter into a PRN monitoring contract.
• Confidentiality: The PRN files are strictly confidential. If the professional complies with the terms of their contract (treatment, random drug screens, practice restrictions), the TSBP is not notified, and no disciplinary action is taken against the license. This is a "safe harbor" that protects careers while ensuring public safety.
• Contract Requirements: A typical PRN contract lasts 2 to 5 years. It mandates outpatient or inpatient rehabilitation, regular attendance at support groups (like AA/NA), and random drug testing. It may also impose practice restrictions (e.g., prohibiting the pharmacist from acting as PIC or working alone).
• Reporting Obligation: If a pharmacist has knowledge that a colleague is impaired and practicing, they must report them. Reporting the colleague to the PRN satisfies the reporting requirement and allows the colleague to get help confidentially. However, if the colleague refuses to cooperate or violates the PRN agreement, the PRN must report them to the TSBP, resulting in public disciplinary proceedings.